𝔖 Bobbio Scriptorium

✦ LIBER ✦

Design and Methodology of the PURSUIT Trial: Evaluating Eptifibatide for Acute Ischemic Coronary Syndromes

✍ Scribed by Robert A Harrington; MD

Book ID: 113978700
Publisher: Elsevier Science
Year: 1997
Tongue: English
Weight: 398 KB
Volume: 80
Category: Article
ISSN: 0002-9149
DOI: 10.1016/s0002-9149(97)00575-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Impact of Eptifibatide on Early Ischemic

Impact of Eptifibatide on Early Ischemic Events in Acute Ischemic Coronary Syndromes: A Review of the IMPACT II Trial

✍ James E. Tcheng; MD 📂 Article 📅 1997 🏛 Elsevier Science 🌐 English ⚖ 675 KB

Design and methodology of the ESPRIT tri

Design and methodology of the ESPRIT trial: Evaluating a novel dosing regimen of eptifibatide in percutaneous coronary intervention

✍ J.Conor O’Shea; Mina Madan; Warren J. Cantor; Cynthia M. Pacchiana; Sally Greenb 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 105 KB

Evaluation of a novel anti-ischemic agen

Evaluation of a novel anti-ischemic agent in acute coronary syndromes: Design and rationale for the Metabolic Efficiency with Ranolazine for Less Ischemia in Non–ST-elevation acute coronary syndromes (MERLIN)-TIMI 36 trial

✍ David A. Morrow; Benjamin M. Scirica; Ewa Karwatowska-Prokopczuk; Allan Skene; C 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 203 KB

Evaluation of a novel anti-ischemic agen

Evaluation of a novel anti-ischemic agent in acute coronary syndromes: Design and rationale for the Metabolic Efficiency with Ranolazine for Less Ischemia in Non–ST-elevation acute coronary syndromes (MERLIN)-TIMI 36 trial

✍ David A. Morrow; Benjamin M. Scirica; Ewa Karwatowska-Prokopczuk; Allan Skene; C 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 205 KB

UPFRONT CLOPIDOGREL USE AND THE EFFICACY

UPFRONT CLOPIDOGREL USE AND THE EFFICACY AND SAFETY OF EARLY EPTIFIBATIDE USE IN PATIENTS WITH ACUTE CORONARY SYNDROME: AN ANALYSIS FROM THE EARLY VERSUS DELAYED PROVISIONAL EPTIFIBATIDE IN ACUTE CORONARY SYNDROMES (EARLY ACS) TRIAL

✍ Tracy Wang; Jennifer A. White; Robert P. Giugliano; Pierluigi Tricoci; Robert A. 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 87 KB

Design and rationale of the MICHELANGELO

Design and rationale of the MICHELANGELO Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)–5 trial program evaluating fondaparinux, a synthetic factor Xa inhibitor, in patients with non–ST-segment elevation acute coronary syndromes

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 758 KB